DemoQuillon Therapeutics is a fictional company on a reserved .example domain. Every source, value and number on this page is illustrative, produced by the real methodology from invented evidence.
Quillon Therapeutics
UnclaimedClinical-stage biotechnology company developing RNA therapies for rare kidney diseases.
An estimate of how reliably the assessed digital ecosystem represents Quillon Therapeutics: the accuracy of what people and machines encounter, weighted by how much each fact matters and how often each surface is seen. Shown as an index until calibrated.
Only 54% of what matters about Quillon Therapeutics could be assessed. The Score describes that part well; the rest is unresolved, not confirmed.
The Score measures how reliably Quillon Therapeutics is represented. Evidence Coverage is how much of its reality could be assessed confidently.
- 0material gaps
- 1conflicting claim
- 4unresolved
11 claims · 29 observations · 11 sources · Scored 8 Sept 2026 · Methodology drs-0.2
Diagnostics
How diagnostics are measuredSix views that explain the Score. They are not averaged into it. Consistency in particular never raises a Score: sources can agree on something wrong.
- AccuracyAre important company facts represented correctly?89Medium confidence · 6 claims
- ConsistencyDo important sources agree?91Medium confidence · 6 claims
- EvidenceAre important company claims sufficiently supported?86Medium confidence · 6 claims
- AuthorityAre credible and authoritative sources reinforcing those claims?81Medium confidence · 6 claims
- DiscoverabilityCan the right company, products and information actually be found?59High confidence · 1 claim
- RepresentationDo search and AI systems describe the company correctly?73Medium confidence · 3 claims
The strongest findings
All 11 claims and their evidenceWhat was observed, and where. Open a finding to see every source behind it.
-
Clinical stage not independently evidenced
Quillon’s website states that QL-101 is in Phase 1. No trial registry entry, publication or press coverage checked confirms the stage, so the claim remains unresolved rather than wrong.
Inspect evidenceHide evidenceClaim:
QL-101 → pipeline_stage → QL-101 in Phase 1Not yet confirmed by the companyLead programme stage · Quillon Therapeutics states: “QL-101 in Phase 1” Source Representation Assessment Exposure Captured Company websiteObserved QL-101 in Phase 1 Current High 4 Sept 2026 AI answer · assistant APerceived Preclinical Conflict High 2 Sept 2026 Decision: Unresolved · P(stated value is true) 60% · representations accurate 45% · 0 independent supporting origins · flagged for human review
-
Series A only described by Quillon
Quillon’s newsroom announces a €32m Series A in 2026. No independent source checked reports the round, and two of the three AI assistants tested return no funding information.
Inspect evidenceHide evidenceClaim:
Quillon Therapeutics → funding → Series A, €32m (2026)Not yet confirmed by the companyLatest funding · Quillon Therapeutics states: “Series A, €32m (2026)” Source Representation Assessment Exposure Captured Company newsroomObserved Series A, €32m (2026) Current Low 26 Aug 2026 AI answer · assistant BPerceived Not stated Not found High 24 Aug 2026 AI answer · assistant CPerceived Not stated Not found Medium 22 Aug 2026 Decision: Unresolved · P(stated value is true) 60% · representations accurate 60% · 0 independent supporting origins
-
Research partnership has no second source
Quillon’s website names a research collaboration with a university medical centre. The partner’s own pages and the press checked do not mention it.
Inspect evidenceHide evidenceClaim:
Quillon Therapeutics → partnership → Research collaboration with Aldermoor University HospitalNot yet confirmed by the companyResearch partnership · Quillon Therapeutics states: “Research collaboration with Aldermoor University Hospital” Source Representation Assessment Exposure Captured Company websiteObserved Research collaboration with Aldermoor University Hospital Current High 23 Aug 2026 Industry publicationEvidenced Not stated Not found Medium 21 Aug 2026 Decision: Unresolved · P(stated value is true) 60% · representations accurate 60% · 0 independent supporting origins
-
Category is represented correctly
Quillon describes itself as a clinical-stage biotechnology company developing RNA therapies. Crunchbase, an industry publication and the AI assistant that recognised Quillon all describe it the same way.
Inspect evidenceHide evidenceClaim:
Quillon Therapeutics → primary_category → Clinical-stage biotechnology companyNot yet confirmed by the companyPrimary category · Quillon Therapeutics states: “Clinical-stage biotechnology company” Source Representation Assessment Exposure Captured Company websiteObserved Clinical-stage biotechnology company Current High 7 Sept 2026 Industry publicationEvidenced Clinical-stage biotech developing RNA therapies Aligned Medium 3 Sept 2026 CrunchbaseEvidenced Biotechnology company Aligned Medium 5 Sept 2026 AI answer · assistant APerceived Biotechnology company developing RNA therapies Aligned High 1 Sept 2026 AI answer · assistant BPerceived Rare-disease drug developer Partial High 30 Aug 2026 Decision: Aligned · P(stated value is true) 98% · representations accurate 88% · 2 independent supporting origins
Your Score is a snapshot. The internet keeps changing.
SIGNAL continuously watches search, brand, mentions, evidence and AI representation, identifies important changes, and tells you what deserves action.
Work at Quillon Therapeutics? Claim the company.
Verify important facts, resolve unknowns and improve Evidence Coverage. Claiming is free, and it is how Business Reality gets established: the Score can only measure against facts someone at the company has confirmed.
- Confirm or correct the 5 claims that are unresolved or disputed
- Your answers stay private unless Quillon Therapeutics chooses to publish them
- Colleagues can join once the company is claimed
Your claim is pending Verify to start confirming facts.
Continue verificationIn review We’ll verify by hand, because it is not at @quillon.example. We’ll email you.
Help resolve these claims
You are verified as . Each answer becomes evidence about Business Reality, reviewed by an analyst before it counts fully. It never sets the Score directly. Answers are private to Quillon Therapeutics unless you choose to publish them.
Projection from your answers, using the published methodology. The Score is not recalculated live: answers apply at the next Score run. Confirming a fact can lower the Score, when the wider web disagrees with it. That is the Score working.
Benchmarks
How Quillon Therapeutics compares with companies like it.
- Your Score
- 87
- Life sciences median
- 66
- Top quartile
- 78+
Evidence Coverage 54%, against a Life sciences median of 58%.
Illustrative cohorts. Benchmarks are published once enough companies in a cohort have been scored.
Score history
First Score. History starts from this run.
- September 2026 drs-0.28754% coverage
Scores are re-run periodically. Continuous monitoring is what PageRadar SIGNAL is for.
Share this Score
Send it to the people who own the story: brand, communications, SEO, leadership.
Want to understand what’s lowering a Score?
PageRadar applies the Digital Reality Gap framework through search strategy, Digital Reality Audits, remediation and SIGNAL. A review starts from this Score.
Digital Reality Score 87/100 and Evidence Coverage 54% were calculated on 08 Sep 2026 with methodology drs-0.2, from 29 observations across 11 sources. An automated Score cannot know every fact about a business: unknown claims stay unresolved rather than being treated as wrong. Read the methodology and the Digital Reality Gap framework it is built on.